⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294124 | 0.83 | — | — | |
| SCHEMBL789463 | 0.80 | QPCT (0.32) | — | |
| SCHEMBL3832318 | 0.80 | — | — | |
| SCHEMBL12310244 | 0.80 | — | — | |
| SCHEMBL64394 | 0.80 | — | — | |
| SCHEMBL2058199 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL28976306 | 0.78 | TDP1 (0.30) | — | |
| SCHEMBL16071178 | 0.78 | — | — | |
| Iodide SCHEMBL28475998 | 0.78 | TDP1 (0.30) | — | |
| SCHEMBL16090808 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4136074-A1 | INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-02-22 | — | — | EP | claimed |
| WO-2021209481-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-21 | — | — | WO | claimed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | claimed |
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | claimed |
| EP-3601282-A1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | claimed |
| US-20180327425-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | claimed |
| WO-2018178041-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-04 | — | — | WO | claimed |
| EP-2411387-B1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | VETDC INC (US) | 2015-08-19 | — | — | EP | claimed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | claimed |
| EP-2627635-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051090-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | claimed |
| EP-2411387-A2 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | claimed |
| WO-2010110685-A2 | PYRIMDDINYL AND 1,3,5-TRIAZINYL BENZIMTOAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | claimed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | claimed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-0636142-A1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021209-A1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |